Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Creatine, Placebo.
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Brazil
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Phase III, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of Creatine Supplementation in Attenuating Chemotherapy-related Cognitive Decline in Patients With Early-stage Breast Cancer Undergoing Chemotherapy.
Overview
The goal of this clinical trial is to evaluate whether oral creatine supplementation can prevent chemotherapy-related cognitive impairment in patients with early-stage breast cancer undergoing neoadjuvant or adjuvant chemotherapy. The main questions it aims to answer are: * Does creatine supplementation reduce the occurrence and severity of chemotherapy-related cognitive impairment, as measured by patient-reported cognitive function? * Does creatine supplementation preserve objective cognitive performance compared with placebo during and after chemotherapy? Researchers will compare creatine supplementation (5 g/day) with placebo to assess differences in cognitive outcomes, safety, and exploratory biological markers. Participants will: * Receive oral creatine or placebo starting 7 days before chemotherapy and continuing until 12 months after chemotherapy completion * Complete patient-reported cognitive assessments and objective neuropsychological tests at predefined time points * Undergo clinical follow-up for safety and oncologic outcomes * Provide blood samples for biomarker analyses and stool samples for gut microbiota assessment * Undergo brain magnetic resonance imaging at selected study visits
Interventions
- Drug Creatine
Oral creatine monohydrate supplementation administered at a fixed dose of 5 g per day, dissolved in water and taken once daily. The intervention starts 7 days before initiation of neoadjuvant or adjuvant chemotherapy and continues through chemotherapy and up to 12 months after chemotherapy completion. The intervention is designed to evaluate the preventive effect of creatine on chemotherapy-related cognitive impairment, with longitudinal cognitive, clinical, imaging, and translational assessment - Other Placebo
Oral placebo powder matched in appearance, taste, and packaging to the investigational product, administered once daily dissolved in water. The placebo is initiated 7 days before the start of neoadjuvant or adjuvant chemotherapy and continued through chemotherapy and up to 12 months after chemotherapy completion. The placebo contains no active ingredients and is used as the comparator to assess the preventive effect of creatine supplementation on chemotherapy-related cognitive impairment.
Primary outcome measures
- Change in patient-reported cognitive function [Time frame: Baseline and 1 month after completion of chemotherapy]
Eligibility criteria
Inclusion criteria
- Age ≥18 years.
- Histologically confirmed invasive breast cancer (stages I-III).
- Indication for neoadjuvant or adjuvant chemotherapy containing an anthracycline or a taxane.
- Targeted therapies and hormone therapy are permitted according to clinical indication.
- Ability to provide informed consent and comply with study procedures.
- ECOG performance status 0-2.
- Ability to maintain adequate hydration.
Exclusion criteria
- Prior neurologic conditions that may impair cognitive assessment, including previous stroke, dementia, traumatic brain injury with neurologic sequelae, or other neurologic disorders affecting cognition.
- Uncorrected sensory impairments that preclude cognitive assessment and/or completion of study instruments.
- History of uncontrolled psychiatric disorders that may interfere with cognitive evaluation.
- Creatinine clearance <60 mL/min, calculated using the Cockcroft-Gault formula.
- Known liver disease.
- Pregnancy.
- Heart failure.
- Presence of ascites.
- Inflammatory bowel disease.
- Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).
- Lactation.
- Chronic use of immunosuppressive agents, including doses greater than 10 mg/day or equivalent.
- Prior chronic creatine supplementation within the last 3 months.
- Known allergy to any component of the supplement or placebo.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Supportive care
Study locations
Brazil · 1 center
- Instituto D'Or de Pesquisa e Ensino de São Paulo — São Paulo
Identifiers
NCT: NCT07372144 · IARA NUP 25000.193607/2025-11